CYBB and metabolic dysfunction-associated steatotic liver disease: In summary, liraglutide has anti-NAFLD effects in vivo and vitro, which is achieved by modulating RAGE/NOX2, thereby reducing ROX, apoptosis and inflammation in liver cells and suppressing the proliferation and activation of hepatic stellate cells, which provides new sights in the mechanism of liraglutide in NAFLD.